The Landscape of EGFR Pathways and Personalized Management of Non-small-cell Lung Cancer

Liang Cheng; Shaobo Zhang; Riley Alexander; Yongxue Yao; Gregory T MacLennan; Chong-xian Pan; Jiaoti Huang; Mingsheng Wang; Rodolfo Montironi; Antonio Lopez-Beltran


Future Oncol. 2011;7(4):519-541. 

In This Article

Future perspective

The advent of EGFR TKI therapy has provided a powerful new treatment modality for NSCLC. At present, testing of EGFR and its downstream effectors is performed to assist clinicians in selecting appropriate treatment regimens for their patients. Determination of the specific alterations in the EGFR pathway will be accepted as standard practice in selecting patients for certain targeting agents, both in the prediction of the clinical outcome of the patients and in the classification of NSCLC. Therapies targeting EGFR or its key downstream pathway effectors may become standard therapies in subsets of NSCLC patients in the near future. With the extensive studies performed on the mechanism of EGFR pathway alteration and carcinogenesis of NSCLC, we are about to bridge the gap between genetic findings and clinical pathological parameters, leading to personalized management. Along with the understanding of the mechanisms of pharmacotherapy and how molecular resistance evolves, it is anticipated that EGFR-targeted therapies will be specifically tailored to individual patients based on the presence or absence of critical mutations in order to maximize therapeutic efficacy and improve overall survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: